Literature DB >> 26062100

Intratunical Injection of Genetically Modified Adipose Tissue-Derived Stem Cells with Human Interferon α-2b for Treatment of Erectile Dysfunction in a Rat Model of Tunica Albugineal Fibrosis.

Ahmet Gokce1,2, Zakaria Y Abd Elmageed1, George F Lasker3, Mostafa Bouljihad4, Stephen E Braun4, Hogyoung Kim1, Philip J Kadowitz3, Asim B Abdel-Mageed1, Suresh C Sikka1, Wayne J Hellstrom1.   

Abstract

INTRODUCTION: Peyronie's disease (PD) has frequently been associated with erectile dysfunction (ED) and may further compromise coitus. AIM: To investigate the efficacy of intratunical injection of genetically modified rat adipose tissue-derived stem cells (ADSCs) expressing human interferon α-2b (ADSCs-IFN) in decreasing fibrosis and restoring erectile function in a rat model of tunica albugineal fibrosis (TAF).
METHODS: A total of 36 Sprague-Dawley rats (12 weeks old; 300-350 g) were randomly divided in six equal groups: (i) sham group (50 μL saline-injected into the tunica albuginea [TA]); (ii) TAF group (transforming growth factor [TGF]-β1 [0.5 μg/50 μL] injected into the TA); (iii) TGF-β1 plus 5 × 10(5) control ADSCs injected same day; (iv) TGF-β1 plus 5 × 10(5) ADSCs-IFN injected same day; (v) TGF-β1 plus 5 × 10(5) control ADSCs injected after 30 days; and (vi) TGF-β1 plus 5 × 10(5) ADSCs-IFN injected after 30 days. Rat allogeneic ADSCs were harvested from inguinal fat tissue. MAIN OUTCOME MEASURES: Forty-five days following the TGF-β1 injection, erectile function was assessed, and penile tissues were harvested for further evaluations.
RESULTS: In the same-day injection groups, intratunical injection of ADSCs and ADSC-IFN improved erectile response observed upon stimulation of cavernous nerve compared with TAF group. Intratunical ADSC-IFN injection at day 30 improved erectile responses 3.1, 1.8, and 1.3 fold at voltages of 2.5, 5.0, and 7.0, respectively, when compared with TAF group. Furthermore, at voltages of 2.5 and 5.0, treatment on day 30 with ADSCs-IFN improved erectile responses 1.6- and 1.3-fold over treatment with ADSCs alone. Local injection of ADSCs or ADSCs-IFN reduced Peyronie's-like manifestations, and these effects might be associated with a decrease in the expression of tissue inhibitors of metalloproteinases.
CONCLUSION: This study documents that transplantation of genetically modified ADSCs, with or without human IFN α-2b, attenuated Peyronie's-like changes and enhanced erectile function in a rat model of TAF.
© 2015 International Society for Sexual Medicine.

Entities:  

Keywords:  Erectile Dysfunction; Fibrosis; Gene Therapy; Human Interferon α-2b; Peyronie's Disease; Stem Cells; Tunica Albuginea

Mesh:

Substances:

Year:  2015        PMID: 26062100      PMCID: PMC4914049          DOI: 10.1111/jsm.12916

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  25 in total

1.  Adipose tissue-derived stem cell-seeded small intestinal submucosa for tunica albuginea grafting and reconstruction.

Authors:  Limin Ma; Yijun Yang; Suresh C Sikka; Philip J Kadowitz; Louis J Ignarro; Asim B Abdel-Mageed; Wayne J G Hellstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

2.  Defining stem and progenitor cells within adipose tissue.

Authors:  Guiting Lin; Maurice Garcia; Hongxiu Ning; Lia Banie; Ying-Lu Guo; Tom F Lue; Ching-Shwun Lin
Journal:  Stem Cells Dev       Date:  2008-12       Impact factor: 3.272

3.  Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression.

Authors:  A I El-Sakka; H M Hassoba; R J Pillarisetty; R Dahiya; T F Lue
Journal:  J Urol       Date:  1997-10       Impact factor: 7.450

4.  Heparin-enhanced zymographic detection of matrilysin and collagenases.

Authors:  W H Yu; J F Woessner
Journal:  Anal Biochem       Date:  2001-06-01       Impact factor: 3.365

5.  Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis.

Authors:  Wei Zhao; Jun-Jie Li; Da-Yong Cao; Xiao Li; Lin-Ying Zhang; Yong He; Shu-Qiang Yue; De-Sheng Wang; Ke-Feng Dou
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

Review 6.  Rat as an animal model for Peyronie's disease research: a review of current methods and the peer-reviewed literature.

Authors:  E Chung; L De Young; G B Brock
Journal:  Int J Impot Res       Date:  2011-07-21       Impact factor: 2.896

7.  Interferon-alpha gene therapy by lentiviral vectors contrasts ovarian cancer growth through angiogenesis inhibition.

Authors:  Stefano Indraccolo; Veronica Tisato; Valeria Tosello; Walter Habeler; Giovanni Esposito; Lidia Moserle; Laura Stievano; Luca Persano; Luigi Chieco-Bianchi; Alberto Amadori
Journal:  Hum Gene Ther       Date:  2005-08       Impact factor: 5.695

8.  Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury.

Authors:  Yuben Moodley; Daniel Atienza; Ursula Manuelpillai; Chrishan S Samuel; Jorge Tchongue; Sivakami Ilancheran; Richard Boyd; Alan Trounson
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

9.  Intratunical injection of human adipose tissue-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie's disease.

Authors:  Fabio Castiglione; Petter Hedlund; Frank Van der Aa; Trinity J Bivalacqua; Patrizio Rigatti; Hein Van Poppel; Francesco Montorsi; Dirk De Ridder; Maarten Albersen
Journal:  Eur Urol       Date:  2012-09-24       Impact factor: 20.096

10.  An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression.

Authors:  A I El-Sakka; H M Hassoba; R M Chui; R S Bhatnagar; R Dahiya; T F Lue
Journal:  J Urol       Date:  1997-12       Impact factor: 7.450

View more
  13 in total

Review 1.  Adipose Tissue-Derived Stem Cells for the Treatment of Erectile Dysfunction.

Authors:  Ahmet Gokce; Taylor C Peak; Asim B Abdel-Mageed; Wayne J Hellstrom
Journal:  Curr Urol Rep       Date:  2016-02       Impact factor: 3.092

Review 2.  Mesenchymal stem cell-based gene therapy for erectile dysfunction.

Authors:  J H Kim; H J Lee; Y S Song
Journal:  Int J Impot Res       Date:  2016-02-18       Impact factor: 2.896

3.  Intratunical injection of autologous adipose stromal vascular fraction reduces collagen III expression in a rat model of chronic penile fibrosis.

Authors:  Lukman Hakim; Salvatore Fiorenzo; Petter Hedlund; Francesco Montorsi; Trinity J Bivalacqua; Dirk De Ridder; Emmanuel Weyne; David Ralph; Giulio Garaffa; Asif Muneer; Steven Joniau; Maarten Albersen; Fabio Castiglione
Journal:  Int J Impot Res       Date:  2019-04-15       Impact factor: 2.896

Review 4.  --- ---Recent advances in managing Peyronie's disease.

Authors:  Oliver Kayes; Rauf Khadr
Journal:  F1000Res       Date:  2016-09-26

5.  Isoflurane inhalation anesthesia should be a new requirement in intracavernosal pressure detection-the gold standard of erectile function assessment.

Authors:  Jinhong Li; Changjing Wu; Fudong Fu; Xuanhe You; Liang Gao; Romel Wazir; Feng Qin; Ping Han; Jiuhong Yuan
Journal:  Sci Rep       Date:  2017-11-02       Impact factor: 4.379

6.  Stromal Vascular Fraction Combined with Shock Wave for the Treatment of Peyronie's Disease.

Authors:  Elliot B Lander; Mark H Berman; Jackie R See
Journal:  Plast Reconstr Surg Glob Open       Date:  2016-03-02

7.  Research highlights on stem cell therapy for the treatment of Peyronie's disease.

Authors:  Premsant Sangkum
Journal:  Transl Androl Urol       Date:  2016-06

Review 8.  Nonsurgical Interventions for Peyronie's Disease: Update as of 2016.

Authors:  Gregory A Joice; Arthur L Burnett
Journal:  World J Mens Health       Date:  2016-08-23       Impact factor: 5.400

Review 9.  Innovative trends and perspectives for erectile dysfunction treatment: A systematic review.

Authors:  Ezzat A Ismail; Ahmed I El-Sakka
Journal:  Arab J Urol       Date:  2016-05-18

10.  The effect of cavernous nerve traction on erectile function in rats.

Authors:  Hao Li; Liping Chen; Tao Wang; Shaogang Wang; Jihong Liu
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.